Toll-like receptor 7/8

Overview

Toll-like receptors 7 and 8 (TLR7 and TLR8) are single-stranded RNA (ssRNA)-sensing pattern recognition receptors (PRRs) belonging to the toll-like receptor family, a class of innate immune sensors critical for detecting pathogen-associated molecular patterns (PAMPs). Both receptors are endosomal transmembrane glycoproteins expressed predominantly on immune cells, including dendritic cells, monocytes, macrophages, and B cells. TLR7 is preferentially expressed in plasmacytoid dendritic cells, while TLR8 shows higher expression in myeloid dendritic cells and monocytes. Upon binding to viral ssRNA or synthetic agonists, TLR7 and TLR8 signal through the MyD88 adaptor protein, activating NF-κB and IRF transcription factors to drive production of proinflammatory cytokines such as interleukin-6, type I interferons, and other innate immune mediators. Their combined designation as TLR7/8 reflects substantial functional overlap, as dual agonists capable of engaging both receptors — most notably resiquimod (R848) — are widely used in research and clinical development.

TLR7 and TLR8 occupy a central position at the intersection of innate and adaptive immunity. Their activation potently stimulates dendritic cell maturation, enhances antigen cross-presentation, and promotes Th1-polarized adaptive immune responses, properties that have made TLR7/8 agonists attractive as vaccine adjuvants and cancer immunotherapy agents. Conversely, dysregulated or excessive signaling through these receptors — particularly gain-of-function mutations in TLR7 — has been implicated in autoimmune conditions including systemic lupus erythematosus (SLE), positioning TLR7/8 antagonists as a complementary therapeutic avenue. The dual nature of TLR7/8 as both immune activators and drivers of immunopathology makes them high-value targets across oncology, infectious disease, and autoimmunity research.

Focus of Latest Publications

Recent publications have focused on Toll-like receptor 7/8 as both a mechanistic immune target and a therapeutic modulator in infection, cancer, autoimmunity, and vaccine design. Several studies evaluated TLR7/8 agonism to amplify innate and adaptive immunity, including resiquimod/R848 in early-stage melanoma, where intradermal or local delivery was associated with stronger conventional dendritic cell activation and increased release of TNF, interleukin-6, interleukin-10, interleukin-12, interferon-γ, and CXCL10. In postoperative glioblastoma therapy, R848 was incorporated into an ascorbic acid-responsive implantable gel to support sustained local immune activation alongside cytotoxic effects from a copper-based prodrug system. Other work used TLR7/8-containing platforms for vaccination, including intranasal liposomal formulations and polymeric RNA scaffolds that combined TLR7/8 signaling with other pattern-recognition receptor pathways to enhance protective immunity in mouse models.

Drug discovery efforts have also identified new small-molecule TLR7/8 modulators. A pyrazolo[1,5-c]quinazoline scaffold yielded one compound with moderate dual agonist activity at TLR7 and TLR8, while additional analogs acted as dual antagonists, expanding structure-activity knowledge for tricyclic TLR7/8 ligands. Separate medicinal chemistry work produced selective TLR8 antagonists based on pyrimidine and quinazoline chemotypes, with the most potent derivative showing low-nanomolar inhibition of TLR8-mediated responses and favorable physicochemical and metabolic properties. Another study on indole derivatives identified a compound that inhibited hepatitis B virus replication and promoted TLR7 downstream cytokines such as IL-12 and interferon-α in human peripheral blood mononuclear cells, with docking and surface plasmon resonance supporting direct binding to TLR7.

TLR7/8 has also been implicated in disease-associated immune dysregulation. In glioma, TLR8 was identified with MMP9 and LILRB2 as part of a prognostic model linked to neutrophil extracellular trap formation, immune evasion, and an immunosuppressive tumor microenvironment. In Clostridioides difficile infection, Tlr7 emerged among nine core genes associated with toxin A/toxin B-related host-response networks and inflammatory signaling. A case report described recurrent autoimmune hemolytic anemia in a child with a gain-of-function TLR7 mutation, extending the clinical spectrum of TLR7-associated autoimmunity. Together, these studies portray TLR7/8 as a versatile node in inflammatory signaling, with recent work emphasizing its value for adjuvant design, antitumor immunity, antiviral therapy, and the study of immune-mediated disease.

Key Publications

• Jun Integrating machine learning and WGCNA to identify core candidate genes and decipher immune-related molecular networks in TcdA/TcdB-associated CDI. (Antonie van Leeuwenhoek, 2026, PMID 42230843): "Machine learning algorithms further narrowed these to nine core genes: Areg, Ptgs2, Cd40, Tlr7, Aif1, Cxcl10, Il6, Cybb, and Nos2."
• Dec Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma. (Oncoimmunology, 2026, PMID 42093471): "In an effort to identify a more effective DC-activating therapy for women, we compared the in-vitro effects of CPG7909 with those of the TLR7/8 agonist resiquimod/R848 on SLN single cells from female patients."
• May Probing Immune Signatures of Conjugated Pattern Recognition Receptor Ligands Identifies Chimeras with Potent Adjuvant and Antitumor Activities. (Journal of medicinal chemistry, 2026, PMID 42087448): "Among these, chimeric TLR4/TLR7 and TLR7/RIG-I ligands elicited broad innate immune activation in vitro and enhanced antigen-specific immune responses in murine vaccination models."
• May A case of autoimmune hemolytic anemia with acquired functional mutation of the TLR7. (Immunologic research, 2026, PMID 42067661): "This patient's condition contrasts with the six previously documented cases of GOF mutations in the TLR7, thereby expanding the phenotypic spectrum of such mutations and enhancing clinical comprehension of childhood systemic lupus erythematosus (cSLE)."
• Apr Design and Synthesis of New Pyrazolo[1,5-c]quinazolin-5-amines as Potential TLR7/8 Modulators. (ChemMedChem, 2026, PMID 42014047): "TLR7 and 8 agonists are potentially valuable vaccine adjuvants while antagonists show useful activity against autoimmune diseases and cancer."
• Apr Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effect. (Bioorganic & medicinal chemistry, 2026, PMID 42001858): "Mechanism studies indicated that 11r promoted the production of TLR7 downstream cytokines such as IL-12 and IFN-α in human PBMCs."
• Apr Engineering polymeric RNA scaffolds as programmable combinatorial innate immune agonists. (Nucleic acids research, 2026, PMID 41978258): "Synthesized by rolling circle transcription, polyRNAs achieve strong TLR3, TLR7, and RIG-I activation and can enable multivalent patterning of CpG-DNA for further engagement of TLR9 signalling."
• Apr Design, synthesis and biological evaluation of novel pyrimidine and quinazoline-based small-molecule Toll-like receptor 8 antagonists. (European journal of medicinal chemistry, 2026, PMID 41962328): "Here, we report a novel chemotype of selective TLR8 antagonists by replacing isoxazole with pyrimidine in previously reported isoxazole-based antagonists."
• Jun A copper-based ascorbic acid-activatable gel for postoperative glioblastoma therapy. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41942054): "CuTR-gel leveraged the copper-chelating properties of sodium alginate (SA) to co-deliver TPD-Cu (a novel ascorbic acid-activated copper complex prodrug) and R848 (a TLR7/8 agonist)."
• Apr A novel risk model incorporating MMP9, TLR8, and LILRB2 drives neutrophil extracellular trap formation and promotes immune evasion in glioma. (International immunopharmacology, 2026, PMID 41740342): "MMP9, TLR8, and LILRB2 were pinpointed as key regulators and a prognostic model was constructed with robust predictive performance."